Lung Cancer Clinical Trials in Minneapolis

Showing 61-80 of 269 trials

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

NCT04665206

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

Solid Tumor, AdultMesotheliomaNSCLC

Vivace Therapeutics, Inc336 participantsStarted Mar 2021

San Francisco, California, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +9 more locations

ACTIVE_NOT_RECRUITINGPHASE3< 1 mile

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

NCT04303780

A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

Amgen345 participantsStarted Jun 2020

Anaheim, California, United States • Duarte, California, United States • Long Beach, California, United States +271 more locations

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Lung Cancer Trials in Other Cities

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Other Conditions in Minneapolis